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Significance of this study
What is already known about this subject?
 ► Use of a flash glucose monitoring system is often 
associated with a decrease in HbA1c and improved 
well- being.
What are the new findings?
 ► Users report a considerable decrease in disease 
burden, reporting, among others, less hypoglycemic 
episodes and less severe hypoglycemias.
 ► Work absenteeism rate and diabetes- related hospi-
tal admissions decrease by two thirds.
 ► Use of a flash glucose monitoring system for 1 year 
is associated with a significant decrease in HbA1c, 
with the most pronounced improvement in patients 
with the worst metabolic control.
How might these results change the focus of 
research or clinical practice?
 ► HbA1c as a primary end point is important, but, 
health- related quality of life (12- Item Short Form 
Health Surveyv2 and 3- level version of EuroQol 5D) 
and patient- reported outcome measures, including 
hypoglycemic episodes, should be considered as 
possibly even more important end points when as-
sessing the effects of a glucose registering device.
AbStrAct
Introduction The FreeStyle Libre is a flash glucose 
monitoring (FSL- FGM) system. Compared with finger- prick 
based self- monitoring of blood glucose, FSL- FGM may 
provide benefits in terms of improved glycemic control and 
decreased disease burden.
Methods Prospective nationwide registry. Participants 
with diabetes mellitus (DM) used the FSL- FGM system 
for a period of 12 months. End points included changes 
in HbA1c, hypoglycemia, health- related quality of life 
(12- Item Short Form Health Surveyv2 (SF-12v2) and 
3- level version of EuroQol 5D (EQ- 5D- 3L)), a specifically 
developed patient- reported outcome measures (PROMs) 
questionnaire, diabetes- related hospital admission rate 
and work absenteeism. Measurements were performed at 
baseline, and after 6 months and 12 months.
Results 1365 persons (55% male) were included. Mean 
age was 46 (16) years, 77% of participants had type 1 DM, 
16% type 2 DM and 7% other forms. HbA1c decreased 
from 64 (95%CI 63 to 65) mmol/mol to 60 (95%CI 60 
to 61) mmol/mol with a difference of −4 (95% CI −6 to 
3) mmol/mol. Persons with a baseline HbA1c >70 mmol/
mol had the most profound HbA1c decrease: −9 (95% CI 
−12 to to 5) mmol/mol. EQ- 5D tariff (0.03 (95%CI 0.01 to 
0.05)), EQ- VAS (4.4 (95%CI 2.1 to 6.7)) and SF-12v2 mental 
component score (3.3 (95%CI 2.1 to 4.4)) improved. For 
most, PROMs improved. Work absenteeism rate (/6 months) 
and diabetes- related hospital admission rate (/year) 
decreased significantly, from 18.5% to 7.7% and 13.7% to 
2.3%, respectively.
Conclusions Real world data demonstrate that use of 
FSL- FGM results in improved well- being and decreased 
disease burden, as well as improvement of glycemic 
control.
InTRoduCTIon
A major challenge in the treatment of diabetes 
mellitus (DM) is to achieve blood glucose 
levels as close to the physiological as possible 
without increasing the incidence of hypogly-
cemia. Ultimately, this approach leads to less 
microvascular and macrovascular compli-
cations and maintenance of health- related 
quality of life (HRQoL).1 2 Besides insulin 
administration, a very important component 
in DM management is accurate glucose moni-
toring. With self- monitoring of blood glucose 
(SMBG) based on finger- prick testing of capil-
lary blood glucose, testing is often focused 
on premeal glucose concentrations, has a 
limited frequency of use and (largely) relies 
on patient compliance and motivation. In the 
last decade, SMBG is supplemented and even 
supplanted by systems aiming at ‘real time’ 
continuous glucose monitoring (CGM) in the 
interstitial fluid.
In 2014, the FreeStyle Libre flash glucose 
monitor (FSL- FGM, Abbott) system was intro-
duced. There are some major differences 
between FGM and other ‘real- time’ CGM 
systems. Results of the FSL- FGM have to be 
obtained through a reader actively used by the 
user instead of data being relayed automati-
cally to a receiver like in most CGMs. Further-
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Figure 1 Patient selection.
fabrication process, and can be used in the upper arm 
only.3 According to the manufacturer, no further indi-
vidual calibration is needed (and is also not possible).
Dutch healthcare authorities and insurance companies 
currently do consider the evidence on scientific and tech-
nical aspects to be insufficient to warrant reimbursement 
for all persons with DM using insulin therapy.4 Still, both 
the Dutch DM patient organization (Diabetes Vereniging 
Nederland, DVN) and health professionals involved in 
DM management would welcome the FSL- FGM as an 
adjunct to current glucose measurement possibilities. 
Therefore, the initiative was taken to establish a nation-
wide prospective registry of persons with DM using FSL- 
FGM: the FLAsh monitor Registry in The Netherlands 
(FLARE- NL). This initiative was taken by the DVN in 
cooperation with Zilveren Kruis (ZK) Achmea (the largest 
healthcare insurance company in the Netherlands) and 
the Diabetes Research Center in Zwolle.
The aim of this registry was to collect daily life data 
from persons with DM using the FSL- FGM system (prior 
to and during use of FSL- FGM). The current study pres-
ents the 1- year results of the FLARE- NL registry.
PaTIenTs and MeTHods
study design and aims
The FLARE- NL registry has a prospective, observational 
design. The aim of the FLARE- NL registry was to assess 
the effects of use of the FSL- FGM on clinically relevant 
end points, with emphasis on HbA1c (primary outcome), 
and changes in frequency and severity of hypogly-
cemia, HRQoL, and experienced disease burden over 
a period of 1 year. Detailed information concerning the 
FLARE- NL registry has been submitted elsewhere. The 
study protocol was registered at the Dutch trial register. ( 
www. trialregister. nl (NTR6212)).
outcomes
When choosing the parameters to be assessed in this 
study, we strived for a more value- based healthcare 
approach.5 As such, we did not exclusively study medi-
cally defined outcomes, such as changes in HbA1c, but 
also patient- reported outcome measures (PROMs) such 
as disease burden as experienced by individuals with DM.
Outcomes were the change in HbA1c after 6 months 
and 1 year of FSL- FGM use, changes in HRQoL as assessed 
by the 12- Item Short Form Health Surveyv2 (SF-12v2),6 
and the 3- level version of EuroQol 5D (EQ- 5D- 3L),7–9 
the number of hypoglycemic episodes in the previous 
6 months, number of hospitalizations related to DM 
(in the previous year), use of test strips (per day), work 
absenteeism rate (in the previous 6 months), and daily 
functioning in the previous 6 months (including sports 
performance). Furthermore, after consulting a patient 
panel of the DVN, a new questionnaire (‘DVN- PROM’) 
was formulated to allow assessment of the degree of 
disease burden experienced by the study population in 
relation to their DM and especially the need for, and use, 
and usefulness of (continuous) glucose measurements. 
This allows a value- based healthcare approach for rating 
the FSL- FGM system from a user’s perspective. Questions 
on this list are divided into different categories, some of 
them descriptive only and others allowing before and 
after assessment. Although this DVN- PROM has not 
been validated yet, we included this information as an 
important outcome in the current study as it may yield 
relevant information from a user’s perspective.
Population
Adults (≥18 years) with DM using insulin were eligible for 
participation in the registry. The advice to use the FSL- 
FGM was not defined by diabetes type, but by indication 
irrespective of type of diabetes. All subjects were treated 
by a hospital- based diabetes team, had a health insur-
ance with ZK and belonged to one or more prespecified 
targets groups.
The definitions of these target groups (indications for 
FSL- FGM use) were formulated in cooperation with a 
patient panel and the DVN. These indications were:
1. Individuals with ‘hypoglycemia unawareness’ and 
occurrence of moderate- to- severe hypoglycemic epi-
sodes despite an average of six or more measurements 
per day over the past year and intensive support from 
a diabetes team.
2. Individuals with unexpected hypoglycemias despite an 
average of six or more measurements per day over the 
past year and despite intensive support from a diabetes 
team.
3. Individuals treated with insulin who, despite maximal 
efforts (frequent blood monitoring and proper life-
style management) and intensive support from their 
diabetes team, do not reach acceptable glycemic con-
trol, as evidenced by a mean HbA1c>70 mmol/mol 
(8.5%) over the year preceding the inclusion.
4. Individuals having an occupation, where sensation 
loss of the fingers by frequent use of home blood glu-
cose meter (HBGM) measurement can cause disabili-
ty, such as musicians, who under other circumstances 
would be advised by the healthcare team to perform 
frequent HBGM daily.
5. Individuals having an occupation, where even relative-
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Table 1 Baseline characteristics of 1365 persons with DM included in the registry
Total T1DM T2DM
Other forms of 
DM
Number (%) 1365 (100) 1054 (77.2) 223 (16.3) 88 (6.5)
  Age, years 46.1 (16.1) 42.8 (15.5) 59.9 (10.8) 52.6 (11.6)
  Male gender, n (%) 744 (54.5) 555 (52.7) 142 (63.7) 30 (48.4)
  Therapy
  Insulin monotherapy 1131 (82.9) 100 (100.0) 88 (39.5) 45 (72.6)
  Insulin and OBGLD 234 (17.1) 63 (5.9) 130 (5.8) 17 (19.3)
Presence of microvascular complications
  Neuropathy, n (%) 230 (16.8) 154 (14.6) 23 (10.3) 6 (9.7)
  Albuminuria, n (%) 244 (17.9) 180 (17.1) 50 (22.4) 10 (16.1)
  Retinopathy, n (%) 247 (18.1) 199 (18.9) 39 (17.5) 6 (9.7)
Presence of cardiovascular disease
  Angina pectoris, n (%) 33 (2.4) 15 (1.4) 14 (6.3) 2 (3.2)
  PCI, n (%) 52 (3.8) 31 (2.9) 14 (6.3) 4 (6.5)
  Myocardial infarction, n (%) 40 (2.9) 23 (2.2) 14 (6.3) 2 (3.2)
  CABG, n (%) 37 (2.7) 23 (2.2) 11 (4.9) 2 (3.2)
  TIA, n (%) 28 (2.1) 14 (1.3) 9 (4.0) 3 (4.8)
  CVA, n (%) 23 (1.7) 14 (1.3) 6 (2.7) 3 (4.8)
  Peripheral arterial disease, n (%) 51 (3.7) 29 (2.8) 18 (8.1) 2 (3.2)
Indication for FSL- FGM use
  Hypoglycemia unawareness 1 156 (11.4) 119 (11.3) 25 (11.2) 8 (12.9)
  Unexpected hypoglycemias 2 410 (30.0) 322 (30.6) 56 (25.1) 25 (40.3)
  HbA1c>70 mmol/mol (8.5%) 3 294 (21.5) 202 (19.2) 80 (35.9) 6 (9.7)
  Unwanted sensation loss of the fingers 4 19 (1.4) 14 (1.3) 5 (2.2) 0 (0.0)
  Occupational hazards with hypoglycemia 5 57 (4.2) 39 (3.7) 11 (4.9) 4 (6.5)
  Individuals eligible for CGM 6 45 (3.3) 40 (3.8) 2 (0.9) 2 (3.2)
  Individuals already using FSL- FGM 7 100 (7.3) 76 (7.2) 14 (6.3) 6 (9.7)
  Multiple indications 284 (20.8) 242 (23.0) 30 (13.5) 11 (17.7)
Data are presented as numbers (%), means (SD) or medians (25th, 75th centiles).
CABG, coronary artery bypass grafting;CGM, continuous glucose monitoring; CVA, cerebral vascular event; DM, diabetes mellitus; FSL- 
FGM, FreeStyle Libre flash glucose monitoring; OBGLD, oral blood glucose lowering drugs;PCI, percutaneous coronary intervention; T1DM, 
type I diabetes mellitus; T2DM, type II diabetes mellitus; TIA, transient ischemic attack.
to a situation endangering themselves and/or others 
(eg, bus and lorry drivers, school teachers, sports train-
ers).
6. Individuals who at the moment are already eligible for 
CGM according to Dutch regulations.
7. Individuals already using FSL- FGM on their own costs, 
but fit with one of the indications described above.
Individuals who were eligible for more than one target 
indication were included in a separate group.
study procedures
The departments of internal medicine and/or diabetes 
centers of all 95 hospitals in the Netherlands were invited 
to include individuals based on the inclusion criteria as 
described above. All these centers were approached by 
means of a letter, providing them extensive information 
with regard to the registry. Every participating hospital 
appointed a single contact person who was responsible 
for collecting data in the center.
At baseline, informed consent of the intended FSL- 
FGM user was obtained. Next, the participant received 
a link to fill out the various questionnaires in the online 
registry. The healthcare provider filled out the data neces-
sary for the registry. These data included demographics 
(age, gender), type of DM, indication for participation, 
level of HbA1c (preceding four values), presence of 
microvascular (neuropathy, nephropathy, retinopathy) 
or macrovascular complications, frequency of HBGM 
measurement, number of DM- related hospitalizations, 
number of hypoglycemic events, absenteeism rate and 
working day losses or reduced functioning due to DM. 
Furthermore, participants were asked to complete three 
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Table 2 Comparison of baseline characteristics between patients with and without a T12 HbA1c measurement.
Baseline HbA1c value (n=1362)
P valueAll (n=1362) T12 missing (n=675) T12 present (n=687)
Age 46.2 (±16.1) 45.0 (±16.3) 47.3 (±15.7) 0.008
Sex (men) 742 (54.5%) 382 (56.6%) 360 (52.4%) 0.128
DM type
  1 1051 (77.2%) 508 (75.3%) 543 (79.0)
  2 223 (16.4%) 124 (18.4%) 99 (14.4)
  LADA 62 (4.6%) 29 (4.3%) 33 (4.8)
  MODY 7 (0.5%) 4 (0.6%) 3 (0.4)
  Others 19 (1.4%) 10 (1.5%) 9 (1.3) 0.357
Indication
  Hypoglycemia unawareness 1 156 (11.5%) 83 (12.3%) 73 (10.6%
  Unexpected hypoglycemias 2 410 (30.1%) 192 (28.4%) 218 (31.7%)
  HbA1c>70 mmol/mol (8.5%) 3 294 (21.6%) 162 (24.0%) 132 (19.2%)
  Unwanted sensation loss of the fingers 4 19 (1.4%) 9 (1.3%) 10 (1.5%)
  Occupational hazards with hypoglycemia 5 57 (4.2%) 29 (4.3%) 28 (4.1%)
  Individuals eligible for CGM 6 43 (3.2%) 22 (3.3%) 21 (3.1%)
  Individuals already using FSL- FGM 7 100 (7.3%) 41 (6.1%) 59 (8.6%)
  Multiple indications 283 (20.8%) 137 (20.3%) 146 (21.3%) 0.262








Indication: (1) Individuals with ‘hypoglycaemia unawareness’ and occurrence of moderate to severe hypoglycemic episodes despite 
an average of six or more measurements per day over the past year and intensive support from a diabetes team. (2) Individuals 
with unexpected hypoglycemias despite an average of six or more measurements per day over the past year and despite intensive 
support from a diabetes team. (3) Individuals treated with insulin who, despite maximal efforts (frequent blood monitoring and proper 
lifestyle management) and intensive support from their diabetes team, do not reach acceptable glycemic control, as evidenced by a 
mean HbA1c>70 mmol / mol (8.5%) over the year preceding the inclusion. (4) Individuals having an occupation, where sensation loss 
of the fingers by frequent use of HBGM can cause disability, such as musicians, who under other circumstances would be advised 
by the healthcare team to perform frequent HBGM daily. (5) Individuals having an occupation, where even relatively rarely occurring 
hypoglycemic episodes would lead to a situation endangering themselves and/or others (eg, bus and lorry drivers, school teachers, 
sports trainers). (6) Individuals who at the moment are already eligible for CGM according to the Dutch regulations. (7) Individuals 
already using the FSL- FGM on their own costs, but fit with one of the indications as described above. Subjects who were eligible for 
more than one target indication were included in a separate group.
CGM, continuous glucose monitoring; DM, diabetes mellitus; FSL- FGM, FreeStyle Libre flash glucose monitoring; HBGM, home blood 
glucose meter; LADA, Latent Autoimmune Diabetes in Adults; MODY, maturity- onset diabetes of the young; T12, 12 months.
the DVN- PROM. The questions as asked in the DVN- 
PROM can be found in online supplementary 1. No cut- 
off points were formulated beforehand with regards to 
the possible clinically relevant differences in the ques-
tionnaires used.
After 6 months and 12 months participants and 
healthcare providers were asked to report HbA1c results 
from the preceding 6 months. In addition, participants 
were asked to report changes in the presence of compli-
cations, the number of diabetes- related hospitalizations 
in the previous period, hypoglycemias (<3 mmol/L; 
(54 mg/dL)) in 3 months before filling out question-
naires, work absenteeism rate (any work- associated 
period of absence in the prior 6 months) and actual 
amount of working days absent in prior 6 months, or 
reduced functioning (including sports performance) 
due to dysregulation of DM, and the SF-12 v2, EQ- 5D- 3L, 
and DVN- PROM.
statistical analysis
Q- Q plots (detrended) and histograms were used to deter-
mine if the tested variable had a normal distribution or 
not. Descriptive statistics include number (percentage), 
mean (SD) and median (IQR (25th, 75th centiles)). In 
order to compare persons with measurements at baseline 
only and with measurements both at baseline and after 
12 months, Fisher’s exact test was used in case of categor-
ical data; and in the case of continuous data, Student’s 
t- test or Mann- Whitney U test were used if the data were 
distributed normally or skewed, respectively.
Linear mixed models with Bonferroni correction were 
used to calculate estimated values and to test differences 
between the three moments in time (t=0, t=6 months and 
t=12 months). Unadjusted and, as a sensitivity analysis, 
age- adjusted and gender- adjusted linear mixed model 
analyses were performed. In the present manuscript only 
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Table 3 Observed and estimated HbA1c concentrations during the study period
Baseline 6 months 12 months Difference (12 months)
All patients
  Observed 62 (55 to 72) 58 (52 to 65) 58 (52 to 66)
  Number 1362 790 687
  Estimated 64.1 (62.5 to 64.9) 59.2 (58.4 to 60.2) ** 60.1 (59.2 to 61.1) ** −4.0 (–5.5 to –2.6)
T1DM
  Observed 62 (54 to 71) 57 (51 to 65) 58 (53 to 66)
  Number 1051 628 543
  Estimated 63.5 (62.7 to 64.3) 59.2 (58.2 to 60.1) ** 60.2 (59.1 to 61.3) ** −3.3 (–4.9 to –1.7)
T2DM
  Observed 67 (56 to 78) 61 (53 to 67) 62 (53 to 69)
  Number 223 114 99
  Estimated 68.2 (66.3 to 70.8) 61.2 (58.6 to 63.8) ** 62.0 (59.2 to 64.7) * −6.2 (–10.3 to –2.1)
Other forms of DM
  Observed 61 (51 to 71) 57 (51 to 63) 55 (50 to 62)
  Number 88 48 45
  Estimated 62.2 (59.6 to 64.8) 56.1 (52.6 to 59.6)* 56.2 (52.6 to 59.8) * −6.0 (–11.5 to –0.6)
Values are presented as numbers, medians (25th, 75th centiles) and estimated means (difference) (95% CI). Data are presented as observed 
data and estimated data using the linear mixed model. HbA1c concentrations are presented in mmol/mol.
*p<0.05 as compared with baseline; **p<0.001 as compared with baseline.
DM, diabetes mellitus; T1DM, type I diabetes mellitus; T2DM, type II diabetes mellitus.
age- adjusted and gender- adjusted linear mixed model 
analyses are presented in online supplementary 2.
A p value<0.05 was considered statistically significant. 
All statistical analyses were performed with SPSS software 
(IBM SPSS Statistics for Windows, V.25.0. Armonk, New 
York, USA).
ResulTs
From June 13, 2016 to July 12, 2017 a total of 1669 partic-
ipants were included from 88 hospitals throughout the 
Netherlands. Because of errors in the application proce-
dure (n=127), incomplete applications (n=9), refusal 
to participate in the registry (n=145) or lack of interest 
in participating in the registry (n=23) 304 subjects were 
excluded from the current analyses (figure 1), leaving 
1365 participating subjects to be analyzed at baseline.
As presented in table 1, mean age at baseline of the 
1365 (55% male) subjects was 46.1 (16.1) years. Type 
1 DM (T1DM) (77.2%) was the most common form of DM 
while 16.3% had type 2 DM (T2DM) and 6.5% (n=88) had 
another form of DM such as latent autoimmune diabetes in 
adults (n=62), maturity- onset diabetes of the young (n=7), 
or unknown (n=19). Eighty- three per cent of the included 
subjects were treated with insulin alone. Concerning the 
different groups of indications for FSL- FGM use, indi-
cations 2 (30.0%), 3 (21.5%) and 1 (11.4%) were most 
common (see table 1). In addition, 20.8% of patients had 
more than one indication for FSL- FGM use.
The baseline characteristics of patients with and without 
a T12 HbA1c measurement are presented in table 2 to allow 
comparison of the population missing T12 data with the 
analyzed population with T12 data present. The patients 
analyzed at T12 were slightly older and had a slightly lower 
HbA1c, but differences were minor.
Overall, the HbA1c concentration decreased from 
64.1 (95% CI 62.5 to 64.9) mmol/mol before the use 
of FSL- FGM to 59.2 (95% CI 58.4 to 60.2) mmol/mol 
after 6 months (p<0.001) and 60.1 (95% CI 59.2 to 61.1) 
mmol/mol after 12 months (p<0.001) (table 3), resulting 
in an overall difference in HbA1c over the study period 
of −4.0 (95%CI −5.5 to 2.6) mmol/mol.
The decrease in HbA1c was present among all types of 
DM: −3.3 (95%CI −4.9 to 1.7) mmol/mol for persons with 
T1DM, −6.2 mmol/mol (95% CI −10.3 to 2.1) for persons 
with T2DM and −6.0 (95%CI −11.5 to 0.6) mmol/mol for 
persons with other forms of DM.
When looking at HbA1c changes within different 
groups of indications of FSL use, maximum impact was 
present within group 3 with an HbA1c reduction of −8.6 
(95% CI −11.8 to to 5.4) mmol/mol. In group 2 and the 
group with multiple indications for FSL use there was 
also a decrease in HbA1c, while HbA1c remained stable 
in groups 1, 4, 5, 6 and 7 (table 4).
Data concerning the course of indices of disease burden 
are presented in table 5. Both the SF-12v2 (mental compo-
nent score) as well as the EQ- 5D- 3L (scores divided into 
assessment of the answers to the five questions and the 
health evaluation using a visual analogue scale (EQ- VAS)) 
showed significant improvements in outcomes, whereas the 









pen Diab Res Care: first published as 10.1136/bmjdrc-2019-000809 on 9 December 2019. Downloaded from 
6 BMJ Open Diab Res Care 2019;7:e000809. doi:10.1136/bmjdrc-2019-000809
Emerging Technologies, Pharmacology and Therapeutics
Table 4 Observed and estimated HbA1c outcomes in the different groups of indications for FSL- FGM use
Indication for FSL- 
FGM use Baseline 6 months 12 months Difference (12 months)
Hypoglycemia unawareness 1
  Observed 56.6 (50.0 to 63.0) 55.0 (49.0 to 62.0) 55.0 (49.2 to 62.0)
  Estimated 57.4 (55.8 to 59.0) 55.7 (53.6 to 57.9) 56.9 (54.5 to 59.3) −0.5 (–4.0 to 3.0)
  Number 156 86 73
Unexpected hypoglycemias 2
  Observed 58.0 (52.0 to 63.0) 55.0 (50.0 to 61.0)** 55.0 (51.0 to 62.0)**
  Estimated 58.0 (57.2 to 58.9) 55.4 (54.3 to 56.5) 56.2 (55.0 to 57.3) −1.9 (–1.1 to –0.2)
  Number 410 252 218
HbA1c>70 mmol / mol (8.5%) 3
  Observed 76.0 (71.0 to 85.0) 67 (61.0 to 76.8)** 67.5 (61.0 to 76.0)**
  Estimated 79.1 (77.6 to 80.5) 70.0 (67.9 to 72.0) 70.4 (68.3 to 72.6) −8.6 (–11.8 to –5.4)
  Number 294 144 132
Unwanted sensation loss of the fingers 4
  Observed 66.0 (53.0 to 78.0) 61.0 (51.0 to 71.8) 67.5 (58.0 to 73.0)*
  Estimated 68.8 (60.0 to 77.5) 61.6 (49.5 to 73.7) 65.6 (53.5 to 77.7) −3.2 (–21.6 to 15.3)
  Number 19 10 10
Occupational hazards with hypoglycemia 5
  Observed 60.0 (52.5 to 69.0) 56.0 (49.0 to 62.5)* 57.4 (49.3 to 65.5)
  Estimated 64.0 (60.3 to 67.7) 58.0 (53.4 to 62.6) 58.0 (52.7 to 63.3) −5.9 (–13.9 to 2.0)
  Number 57 37 28
Individuals eligible for CGM 6
  Observed 59.0 (51.0 to 67.0) 57.0 (48.5 to 62.0) 61.0 (51.0 to 65.5)
  Estimated 59.1 (55.6 to 62.5) 57.2 (52.7 to 61.7) 59.1 (54.2 to 61.1) 0.1 (–7.3 to 7.5)
  Number 52 43 21
Individuals already using FSL- FGM 7
  Observed 58.5 (53.3 to 67.0) 56.0 (51.5 to 62.0) 56.0 (52.0 to 63.0)
  Estimated 60.4 (58.3 to 62.5) 57.5 (55.0 to 60.1) 58.2 (55.4 to 60.9) −2.2 (–6.4 to 2.0)
  Number 100 65 39
Multiple indications
  Observed 63.0 (54.0 to 71.0) 58.0 (51.0 to 65.0)** 59.0 (52.0 to 66.0)**
  Estimated 63.2 (61.8 to 64.5) 59.0 (57.2 to 60.7) 59.5 (57.7 to 61.4) −3.6 (–6.5 to –0.8)
  Number 283 171 146
Values are presented as numbers, medians (25th, 75th centiles) and estimated means (difference) (95% CI). Data are presented as observed 
data and estimated data using the linear mixed model. HbA1c concentrations are presented in mmol/mol.
*p<0.05 as compared with baseline; **p<0.001 as compared with baseline. Detailing of indications: see text and Table.
CGM, continuous glucose monitoring; FSL- FGM, FreeStyle Libre flash glucose monitoring.
During 1- year use of the FSL- FGM the percentage 
of patients experiencing any hypoglycemic events 
decreased from 93.5% to 91.0% at 12 months (p<0.05). 
The percentage of DM- related hospital admissions 
decreased from 13.7% to 4.7% (p<0.05). There was 
also a decrease in work absenteeism rate over time: 
from 18.5% to 7.7% (p<0.05). Finally, a decrease in 
the number of test strips used per day for SMBG was 
reported: −2.2 (95%CI −2.6, to 1.7) per day.
In online supplementary 3, data of indices of disease 
burden are shown for T1DM and T2DM separately. As 
presented in online supplementary 2, besides a significant 
increase in the physical component score of the SF-12v2 in 
the age- adjusted and gender- adjusted analyses as compared 
with the unadjusted data, there were no relevant differ-
ences in outcomes after adjustment for age and gender.
A complete list of the questions asked in the DVN- 
PROM is shown in online supplementary 1. Selected 
results are shown in box 1. Results are positive, for 
example, on aspects as self- reported (severe) hypogly-
cemia incidence and measuring before driving, a better 
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Table 5 Changes in indices of disease burden




PCS Observed 50.6 (44.7 to 54.1) 51.6 (45.9 to 54.7)** 51.2 (45.8 to 54.7)*
  Number 1360 1055 680
  Estimated 48.8 (48.4 to 49.2) 49.6 (49.2 to 50.1) 49.4 (48.8 to 49.9) 0.6 (−0.3 to 1.5)
MCS Observed 49.6 (40.6 to 56.4) 51.2 (43.4 to 57.8)* 52.6 (45.1 to 58.6)*
  Number 1360 1055 685
  Estimated 48.0 (47.5 to 48.6) 50.0 (49.4 to 50.7) 51.3 (50.5 to 52.1) 3.3 (2.1 to 4.4)
EQ- 5D- 3L
Dutch Tariff Observed 0.84 (0.77 to 1.00) 0.90 (0.78 to 1.00)* 0.90 (0.78 to 1.00)*
  Number 1360 1056 685
  Estimated 0.83 (0.82 to 0.4) 0.86 (0.85 to 0.87) 0.86 (0.84 to 0.87) 0.03 (0.01 to 0.05)
EQ- VAS Observed 72 (61 to 81) 76 (67 to 82)* 77 (69 to 85)*
  Number 1361 1057 685
  Estimated 68.2 (67.1 to 69.2) 71.5 (70.3 to 72.8) 72.6 (71.1 to 74.2) 4.4 (2.1 to 6.7)
Hypoglycemic events
Presence of any hypoglycemic 








Number of hypoglycemic events in 
past 6 months, n (%)
Observed 30 (10 to 72) 30 (12 to 72) 26 (11 to 70)*
  Number 1266 972 623
  Estimated 54.0 (50.1 to 58.0) 54.8 (50.4 to 59.3) 57.4 (51.9 to 63.0) 3.4 (−4.9 to 11.7)
Use of strips
Strips per day, n (%) Observed 6 (4 to 8) 5 (1 to 7)* 3 (0 to 6)*
  Number 1350 1049 685
  Estimated 6.1 (5.9 to 6.3) 5.0 (4.8 to 5.3) 4.0 (3.7 to 4.3) −2.2 (−2.6 to –1.7)
Hospital admissions
Hospital admissions in past 
12 months, yes, n (%)
187 (13.7) 97 (7.1)** 32 (4.7)**
  Number 1365 1049 681
Number of hospital admissions, n Observed 1.0 (1.0 to 2.0) 1.0 (1.0 to 2.5) 1.0 (1.0 to 2.0)
  Number 187 97 32
  Estimated 0.33 (0.24 to 0.42) 0.30 (0.19 to 0.40) 0.09 (−0.03 to 0.22) −0.24 (−0.43 to –0.04)
Loss of working days
Absenteeism rate in past 6 months, 
yes, n (%)
251 (18.5) 104 (9.8)* 53 (7.7)*
  Number 1360 1056 686
Number of working days lost in last 
6 months
Observed 7 (3 to 25) 9 (3 to 35) 10 (3 to 44)
  Number 247 95 50
  Estimated 34.6 (27.2 to 42.0) 38.2 (26.5 to 50.0) 44.4 (28.1 to 60.8) 9.8 (−12.1 to 31.8)
Values are presented as numbers (%), medians (25th, 75th centiles) and estimated means (difference) (95% CI). Data are presented as observed 
data and estimated data using the linear mixed model.
*p<0.05 as compared with baseline; **p<0.001 as compared with baseline.
EQ- 5D- 3L, 3- level version of EuroQol 5D; EQ- VAS, EQ- visual analogue scale; MCS, Mental Component Score; PCS, Physical Component Score; 
SF-12v2, 12- Item Short Form Health Surveyv2.
in adjusting insulin doses, and less worries for house 
mates and family members.
During the study period, 86 (6.3%) persons reported 
their reason to stop with FSL- FGM use. Reasons for stop-
ping FSL- FGM were high costs (54.7%), insufficient 
convenience (7.0%), inability to control blood glucose 
concentrations (3.5%), a combination of these factors 
(2.4%) or other reasons (32.6%). It should be noted that 
the majority of people ceasing the use of the FSL- FGM did 
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box 1 selected results of diabetes Vereniging nederland 
patient- reported outcome measures (dVn- PRoM) 
comparing baseline to 1 year
 ► No impediment to measure glucose in the presence of strangers: 
from 34.7% to 81.7% (p<0.001).
 ► Deciding what to do best after measuring glucose: improvement 
from 22.9% to 56.7% (p<0.001).
 ► Glucose measurement in a poorly illuminated space is achievable/
workable: from 49.4% to 88.6% (p<0.001).
 ► Measuring glucose before participating in traffic as a driver: usually 
and always: from 40.9% to 75.4% (p<0.001).
 ► 37% reports sporting and exercising more frequently.
 ► 95% reports a better understanding of his or her glucose 
fluctuations.
 ► 77% experiences less hypoglycemias.
 ► 78% experiences less severe hypoglycemias.
 ► 92% finds it easier to regulate glucose around a meal.
 ► 80% adjusts insulin doses more frequently.
 ► 62% reports that house mates and family members are less wor-
ried about their diabetes.
(no obligatory filling out of data was required since this 
was a real life registry without any means of enforce-
ment). An unknown number of users ceased using the 
device due to an allergic reaction on the glue.
dIsCussIon
The FLARE- NL registry provides real life data on the 
effects of 1- year use of the FSL- FGM. A significant decrease 
in the primary outcome measure, HbA1c, was observed, 
with the most pronounced decreases in subjects with the 
highest baseline HbA1c.
Possibly more important from a patient and socioeco-
nomic point of view, are the improvements in HRQoL, 
the decrease in number of patients experiencing hypo-
glycemic events, and the effects on work absenteeism rate 
and diabetes- related hospital admissions. Despite the fact 
that the present version of the FSL- FGM does not contain 
automated alarms or a direct connection with an external 
insulin infusion pump, generally the device is well appre-
ciated by the users in this study as reflected in the answers 
to the non- validated DVN- PROM.
The patients included in the analysis at T12 were 
slightly older and had a slightly lower HbA1c compared 
with the group with missing T12 information. However, 
given the very small differences (see table 2), we do not 
think that the outcomes found in this study are biased by 
selective attrition.
In the whole analyzed group, HbA1c decreased moder-
ately with −4.0 (95% CI −5.5 to to 2.6) mmol/mol. Part of 
this rather moderate effect might be due to the already 
relatively low baseline HbA1c with a mean of 64 mmol/
mol in subjects already trying to comply to a rather inten-
sive control and intervention scheme before starting with 
the FSL- FGM. This may be emphasized by the fact that 
the largest HbA1c decrease is present in subjects with 
the highest baseline HbA1c, although in this last group 
a regression to the mean effect cannot be completely 
excluded. Furthermore, the moderate overall effect on 
HbA1c could well be explained by the fact that multiple 
indications (including frequent hypoglycemic events) 
were included for FSL- FGM use. Indeed, analyses among 
the different groups of FSL- FGM users demonstrate that, 
for instance, there was no decrease of HbA1c among 
patients in group 1 (‘hypoglycaemia unawareness’) 
while a profound HbA1c decrease of −8.6 (95% CI −11.8 
to 5.4) mmol/mol was present in group 3 (‘inadequate 
glycaemic control’).
The reported HbA1c change in the present study 
is rather comparable to the reported changes in other 
studies. For instance, meta- analysis of 363 persons with 
T2DM using insulin (baseline HbA1c 74 mmol/mol) 
by Kroeger et al10 demonstrated a HbA1c decrease of 
10 mmol/mol after at least 3- month use of the FSL- FGM. 
In addition, among 900 persons with T1DM with base-
line HbA1c≥58 mmol/mol FSL- FGM a median decrease 
of −7 mmol/mol was noted during a median study period 
of 245 days.7 In accordance with our study, a relationship 
between baseline HbA1c and rate of decrease was noted 
(r= −0.479, in Kroeger’s study, vs r=−0.494 in our study). 
The current study adds to these data by providing data 
on the effectiveness of FSL- FGM among different types of 
DM and indications for FSL- FGM use.
As for experienced disease burden, virtually all 
outcomes showed positive results.
The improvements in the SF-12v2 Mental Component 
Score, the EQ5D- 3L were significant. Of course, with 
the relatively small differences found, discussion may 
remain with regard to the clinical relevance as opposed 
to significance.
With regard to differences between persons with T1DM 
and T2DM, direction of change was comparable for 
T1DM and T2DM in most indices of disease burden and 
quality of life. A rather large difference is noted in the 
amount of subjects reporting any hypoglycemias: this is 
considerably lower in subjects with T2DM, and there was 
no trend to decrease in this study. Grade of significance, 
in particular among persons with T2DM, is somewhat 
variable; trends are largely comparable, but with smaller 
group sizes, significance is not reached.
In our opinion, the reported effect of less hypogly-
cemic events combined with a neutral effect or a (slight) 
decrease in HbA1c is significant and relevant from a user 
point of view. For all involved parties (users, healthcare 
professionals, and healthcare insurance companies), the 
observed lower diabetes- related hospital admission rate 
can be considered quite a positive result. This finding, 
based on self- reported data, is slightly in contrast with 
the findings in the study of Tyndall et al,11 where hospital 
admission rates show a tendency to increase. In a follow- up 
study (presently in progress), we will try to confirm or 
refute this finding by analyzing the health insurance 
company data. Work absenteeism rate dropped, even 
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the participants are not employed (anymore). When 
restricting the analysis to people 65 years or less of age 
(as a surrogate measure for employment, n=1186), the 
drop in absenteeism rate was still present: 20.4% to 8.3% 
(p<0.001).
While fully acknowledging the fact that we used the 
non- validated (‘DVN- PROM’) questionnaire, most 
patients and healthcare workers may recognize the ques-
tions as being rather representative for daily life barriers, 
impediments and incidents.
As recently stated by Poole, patient- experience data are 
vitally important to both large healthcare organizations 
and small medical practices.12 Obstacles for proper inter-
pretation and chances on bias are plentiful, but still the 
presented results show outcomes which are important 
from patient’s perspective in value- based healthcare.
Moreover, anxiety (which can be the result of the 
perceived disease burden, but definitely is also associated 
with the burden of depression) is correlated to high- cost 
resource use, at least in T2DM. Decreasing anxiety by 
decreasing disease burden might be a factor contributing 
to diminished medical expenditure.13
As can be expected, there are also side effects of the 
devices used, among others, costs, unreliable data, and 
allergies. Besides the reported reasons to cease FSL- FGM 
use, several patients reported (sometimes severe) skin 
reactions. This seems to be due to the type of glue used 
to attach the FSL- FGM to the skin.14
Strengths of our study are the large study population 
(the largest data available in literature to date), the 
participation of the majority of the Dutch hospital orga-
nizations, and the inclusion of both clinical and societal 
aspects when analyzing the effects of the use of the FSL- 
FGM, including the PROM DVN- PROM. Furthermore, 
aspects with regards to quality of life and disease burden 
are included as well.
Definitely, limitations are present as well. First, this 
study can be described as a prospective intervention 
study without a control group and a multitude of missing 
data. To a large extent, the obtained data are patient- 
reported; recall bias may be present and the verity of 
a substantial part of the patient- reported information 
cannot be controlled through other means. In addition, 
participants had to finance half of the costs of the FSL- 
FGM themselves; this inevitably will contribute to bias, 
since the participants probably will be more affluent than 
the average DM population, at least in the Netherlands. 
Many users dropped out and did not report back even 
after 6 months, without reporting a reason for the discon-
tinuation in the register. Since participation for filling 
out the various questionnaires was voluntary, the dropout 
was considerable for that reason as well, especially after 
12 months.
In general and as already mentioned, many data were 
missing in this real life database. Efforts to gain more 
information from the participants and hospitals only 
partly succeeded. Since the participation was voluntary, no 
other means to improve data completeness were applied. 
Finally, it should be mentioned that one of the question-
naires (the ‘DVN- PROM’) used in this study is not vali-
dated. Although the DVN- PROM was non- validated, we 
still find the results valuable and useful as it represents 
the results of collaboration with a DM patient organiza-
tion and FSL- FGM users, and the questions asked are very 
recognizable for both caregivers and patients.
Several steps are already taken to remedy part of the 
limitations. In a follow- up study we plan to combine the 
data as present in the current FLARE- NL registry with 
the reimbursement data of the healthcare insurance 
company to assess the actual effects of FSL- FGM on 
healthcare costs (as represented by reimbursement data). 
This will allow an analysis with regards to diabetes- related 
hospital admission rate, but also allows for other compar-
isons. Anonymization and combining of these databases 
is outsourced in order to prevent any privacy issue.
Furthermore, questionnaires will be sent out again 
2 years after starting with the FSL- FGM to assess the 
effects of ceasing the use of the FSL- FGM.
ConClusIons
It can be concluded, that a large proportion of persons 
with DM, using FSL- FGM, experiences positive effects 
on a wide range of outcome parameters. HbA1c levels 
decreased, while, according to their own reporting, 
patients experienced a lower absenteeism rate, and 
less diabetes- related hospital admission rates. Further-
more, they reported less and less severe hypoglycemias, 
and a more active role toward treatment and treatment 
changes. Of course, these outcomes should not all be 
taken at face value. Acknowledging the several limita-
tions of this study, in our opinion the results are still 
convincing enough to allow the general conclusion that 
the FSL- FGM is a valuable addition to treatment options 
for specific target groups of patients with DM, irrespec-
tive of the type of diabetes.
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